Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies
Bouraoui Y., Ben Jemaa A., Rodriguez G., Ben Rais N., Fraile B., Paniagua R., Sellemi S., Royuela M., Oueslati R.
Aim: The aim of this work was to characterise the immunoexpression of NF-κB (p50/p65) in human prostatic pathologies and to study its profiles of activation among sera prostate specific antigen antigen (PSA) according the three groups: 0-4. ng/mL, 4-20. ng/mL and > 20. ng/mL. Patients and methods: Twenty-four men with benign prostate hyperplasia (BPH); 19 men with prostate cancer (PC) and five men with normal prostates (NP). Immunohistochemical and western blot analysis was performed. Serum levels of PSA were assayed by immulite autoanalyser. Results: In BPH and PC samples, immunoexpressions were observed for NF-κBp65 and NF-κBp50; while in NP samples, only were detected NF-κBp50. PC samples showed immunoreactions to NF-κBp65 and NF-κBp50 more intense (respectively 24.18 ± 0.67 and 28.23 ± 2.01) than that observed in BPH samples (respectively18.46 ± 2.04 and 18.66 ± 1.59) with special localisation in the nucleus. Different profiles of NF-κBp65 immunoexpressions were observed and BPH patients with sera PSA levels between 0-4. ng/mL presented a significant weak percentage compared to BPH patients with sera PSA levels between 4-20. ng/mL and > 20. ng/mL. No immunoreactions to NF-κBp65 were observed in PC patients with sera PSA levels between 4-20. ng/mL. Conclusion: The sensibility of both NF-κB and PSA to inflammation allowed confirming the relationship between these two molecules and its involvement in prostatic diseases progression (inflammatory and neoplasic). © 2011 Elsevier Masson SAS.